New cancer drug AP601 enters early human safety testing

NCT ID NCT07165067

Recruiting now Disease control Sponsor: AP Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025 · Last updated May 23, 2026 · Updated 32 times

Summary

This early-phase study tests the safety of a new drug called AP601 in 36 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find the highest dose that can be given safely. Participants receive one of six dose levels, and the study monitors side effects closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Calvary Mater Newcastle
NOT_YET_RECRUITING

Waratah, New South Wales, 2298, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Epworth HealthCare
RECRUITING

Melbourne, Victoria, 3121, Australia

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Pindara Private Hospital
NOT_YET_RECRUITING

Brisbane, Queensland, 4217, Australia

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID TUMOURS